OBJECTIVES:
Selective serotonin reuptake inhibitors (SSRIs) have been associated with increased risk of osteoporotic-related fractures. Bisphosphonates (BPs) are one of the recommended medications for osteoporosis and fracture prevention. The primary objective of this study was to examine the proportion of BP users who are also on SSRIs and to explore the relationship between concomitant use and patient age among women aged 45 years and older. METHODS: Data from the [2004] [2005] [2006] [2007] [2008] Medical Expenditure Panel Survey (MEPS) was used to examine usage patterns of BPs and SSRIs for women aged Ն45 years. Analyses were based on yearly consolidated data and prescribed medicines files. Weighed descriptive statistics were used to evaluate patterns of medications use and proportions were reported. Age was categorized into two groups: 45-64, and 65-85 years old. RESULTS: In the timeframe examined, 3.5% women in 2004 , 3.8% in 2005 , 4.0% in 2006 , 3.9% in 2007 , and 4.0% in 2008 received bisphosphonates. In the same period, 8.6% women in 2004 , 8.5% in 2005 , 8.1% in 2006 , 7.4% in 2007 , and 7.9% in 2008 received SSRIs. Concomitant use (BPsϩSSRIs) was observed in 0.4% women in 2004 , 0.5% in 2005 , 0.6% in 2006 , 0.6% in 2007 , and 0.6% in 2008 . In 2006 , 2007 , and 2008 , concomitant use of BPsϩSSRIs was higher in the 65-85 age group compared to that of 45-64 years. This pattern may be in large part due to increasing population of older women in the United States. CONCLUSIONS: Concomitant use of BPs and SSRIs in adult women Ն45 years is not uncommon and might be higher in older postmenopausal women. The observed concomitant use presents drug safety challenges surrounding the bone health of postmenopausal women. Studies are needed to investigate the potential interactive effects of SSRIs on BP therapy. 
PIH11 PREVALENCE AND INCIDENCE RATES OF MOST COMMON COMORBID CONDITIONS AMONG PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX: A NAITONAL CLAIM DATABASE ANALYSIS

OBJECTIVES:
Tuberous sclerous complex (TSC) is a multi-system disorder that can affect almost any organ system in the body. The objective of this study is to examine the prevalence and incidence rates of the common co-morbid conditions among patients with TSC. METHODS: We used a large national health care claims database for 39 million commercially insured US populations. Patients with a TSC claim between 2000 and 2009, and continuous enrollment 12 months before and 12 months after their first TSC diagnosis were included in this analysis (These selection criteria lead to the exclusion of those at age less than one). Approximately 40 TSC related clinical conditions were identified using ICD-9 codes or CPT codes. The prevalence and incidence rates of these conditions are assessed and reported. RESULTS: Patients (Nϭ1249) with TSC had mean age of 33.9 years at their 1st TSC diagnosis, and 57.5% were females. The most prevalent comorbid conditions within the first post TSC year were vision disorders (34.8%), benign neoplasm of skin (28.1%), seizure (16.1%), convulsion (15.0%), dyschromia (12.2%), depression (11.1%), cardiac dysrhythmia (9.1%), anxiety (8.6%), sleep disorder (7.8%) and hematuria (6.3%). The conditions with highest incidence rates (per 10,000 patient years) in the same period were benign neoplasm of skin (1,361), vision disorders (1,017), dyschrommia (480), seizure (464), and convulsion (456); subependymal giant cell astrocytoma (160) and Cardiac rhabdomyomas (80) were also observed. CONCLUSIONS: TSC affects multi-systems and organs, and is associated with many comorbid conditions. Vision disorders, benign skin cancer, seizure, convulsion, dyschromia, depression, cardiac dysrhythmia, anxiety, sleep disorders and hematuria are the most prevalent ones in the real world. Managing TSC could be challenging due to its multi-system involvement. Future effort should focus on developing treatment that treat the underlying cause of the disease. 
INDIVIDUAL'S HEALTH -Cost
METHODS:
The analysis compared RAMQ drug expenditures after the introduction of FDC (New Drug Scenario) with an alternative scenario without FDC (Reference Scenario). Treatments in the reference scenario include alpha blockers (tamsulosin, doxazosin, terazosin, alfuzosin), 5␣-reductase inhibitors (finasteride, dutasteride) and their combinations. The treated population was assumed to be equal to the population of men in Quebec aged Ն50 years with moderate to severe symptoms of BPH (estimated at 312,448). In the primary analysis, FDC was assumed to gain 2.5%, 5.8% and 9.3% of BPH market share in the first 3 years after listing with 75% of share gains coming from patients switching from an alpha blocker plus dutasteride, and 25% from patients switching from tamsulosin monotherapy. Oneway sensitivity analysis was performed to quantify the effect of uncertainty around the market shares assumptions. RESULTS: In the primary analysis, adding FDC to RAMQ is projected to result in a cost saving of $0.253M over three years. Assuming only 60% of market share comes from patients currently taking dutasteride plus an alpha blocker, the total incremental BI is $5.879M over 3 years. If FDC gains 90% of its market shares from dutasteride plus an alpha blocker, the BI would results in a cost saving of $6.386M over 3 years. CONCLUSIONS: Based on this budget impact analysis, it may be cost-saving for the RAMQ to switch patients who are treated with combination therapy of separate drugs of dutasteride and an alpha blocker to a FDC of dutasteride and tamsulosin. OBJECTIVES: Epilepsy affects about 3 million people in the United States and accounts for $17.6 billion/year in health care costs. Many antiepileptic drugs (AEDs) are used to treat the disease, but some patients remain refractory. We compared annual overall and epilepsy-related health care costs between refractory and stable epileptic adults. METHODS: We identified adults (ageՆ18years) with epilepsy requiring additional AED therapy (defined as refractory) and not requiring such therapy (stable) from the MarketScan claims database in [2007] [2008] [2009] . An index date was selected during calendar year 2008: the date on which an additional AED was started for refractory patients; and convenience date for stable patients whose AED use was unchanged in the prior year. All pharmacy and medical claims in the post-index year were used to estimate overall costs. Claims with epilepsy in any diagnosis field were used to estimate epilepsy-related costs. Analysis of covariance was used to compare outcomes after adjusting for baseline differences between groups. RESULTS: We identified 1536 refractory and 8571 stable patients (age range: 18-64years; 50.7% vs. 47.6% female; mean Charlson comorbidity index: 0.7 vs. 0.5). Comparing refractory vs. stable patients the total health care costs were $23,238 (SD:$42,894) versus $13,839 (SD:$31,355) per patient-year (PPY) and epilepsy-related costs were $12,399 (SD: $25,773) versus $5,511 (SD:$11,730) PPY (pϽ0.001). Of epilepsy-related costs, $7,257 (SD:$25,202) versus $2,751 (SD:$11,029) PPY were medical and $5,142 (SD:$4,110) versus $2,760 (SD:$3,361) PPY for AEDs (pϽ0.001). After adjusting for age, gender, region, usual care physician specialty, comorbidities and risk factors, overall costs were significantly greater in the refractory compared to stable patients: $7187 (pϽ0.001). CONCLUSIONS: Although both refractory and stable epilepsy patients have a high economic burden, the costs incurred by patients with refractory disease are significantly greater. Epilepsy-related costs comprised under 50% of total costs, suggesting a substantial burden of comorbid conditions and/or under-identification of epilepsy-related utilization.
PIH13 A COMPARISON OF ANNUAL OVERALL AND EPILEPSY-RELATED HEALTH CARE COSTS BETWEEN ADULT PATIENTS WITH DIFFERENTIALLY-CONTROLLED EPILEPSY
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